Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
|Videos|July 22, 2020
The Stakes of Antibiotic Stewardship
Author(s)Grant M. Gallagher
Dr. Pol Vandenbroucke talks about what makes antibiotic stewardship so important to clinicians and researchers.
Advertisement
Segment Description: Dr. Pol Vandenbroucke, Chief Medical Officer for Pfizer’s hospital business unit, talks about what makes antibiotic stewardship so important to clinicians and researchers.
Related Coverage:
The AMR ACTION FUND
More than 20 biopharmaceutical companies are collaborating on an initiative to develop 2-4 antibiotics in 10 years in order to counteract antimicrobial resistance.The AMR Action Fund, an initiative of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), an international body representing the R&D pharmaceutical industry, was announced at simultaneous virtual launch events in Berlin and Washington, DC.“With the AMR Action Fund, the pharmaceutical industry is investing nearly $1 billion to sustain an antibiotic pipeline that is on the verge of collapse, a potentially devastating situation that could affect millions of people around the world,” Chairman and CEO of Eli Lilly and Company and President of IFPMA David Ricks said.
Read full story.
Advertisement
Related to this article
Recent urinary tract infection guideline updates from multiple international
medical societies highlight evolving recommendations, including a major shift
in classification, moving from anatomy- and risk factor–based definitions
toward distinguishing localized from systemic infections.
Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
IDSA/ESCMID panel member Henry Chambers, MD, explains why the new S aureus bacteremia guidance replaces the complicated vs uncomplicated label with risk stratification, and how the statements are akin to the stages of cancer in guiding treatment decisions associated with this bacteremia.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
Widespread antimicrobial use disrupts vital microbial communities that regulate Earth’s biogeochemical cycles, driving antimicrobial resistance, worsening human and environmental health, and significantly contributing to climate change.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
Advertisement
Advertisement